https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=13555

Ledipasvir / Sofosbuvir

Rosuvastatin

Not recommended association.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Ledipasvir / Sofosbuvir may inhibit hepatic transports OATP1B1/B3 and BCRP and increase plasma concentration of Rosuvastatin.

Ledipasvir / Sofosbuvir

Pharmacodynamic effects

–

Recommendations

–

Alternative solution(s)

–

Rosuvastatin

Pharmacodynamic effects

Possible increase of adverse effects.

Recommendations

Association not recommended.

Choose an alternative.

If deemed clinically possible, discontinue treatment with statin during the taking of ledipasvir/sofosbuvir.

Alternative solution(s)

Statin without interaction with all of the medication.

Monitor

Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.

Tests

CK

Lipidic profile

Pharmacokinetic parameters

–

Comment

Ref #3129: a pharmacokinetic study showed an increase of rosuvastatin AUC by 8-fold (+699%) and Cmax by 17.7-fold (+1670%) when co-administered with the GS-9451/ledipasvir/tegobuvir.

Reference
  • 3073
    Ledipasvir/Sofosbuvir (Harvoni), Gilead, Ontario, Canada, 16 avril 2018.
  • 3129
    Kirby B. Transporters : Role in Clinical Development of HCV Compounds. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington DC USA, 19-21 may 2014. Session 6.